Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

Mankind Pharma Limited is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 1.06900
forwardPE 33.74138
debtToEquity 38.11100
earningsGrowth 0.31700
revenueGrowth 0.11800
grossMargins 0.71619
operatingMargins 0.20558
trailingEps 46.20000
forwardEps 71.82872

Mankind Pharma Limited's current ratio being 1.069 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that Mankind Pharma Limited can meet its financial obligations with ease.
Mankind Pharma Limited's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for Mankind Pharma Limited.
With positive gross and operating margins, MANKIND's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
With a forward EPS greater than its trailing EPS, MANKIND is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

MANKIND's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about MANKIND's ability to generate strong results going forward.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


Analysts have maintained a buy bias for MANKIND, which could prompt investors to consider the stock as a viable investment. With this positive outlook, MANKIND is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.